<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442960</url>
  </required_header>
  <id_info>
    <org_study_id>30934</org_study_id>
    <nct_id>NCT02442960</nct_id>
  </id_info>
  <brief_title>Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis</brief_title>
  <official_title>An Open-Label, Dose-Escalation Phase Ib Study Evaluating the Safety and Preliminary Efficacy of Oral SA100 in the Treatment of Patients With Mild-to-Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given
      orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of
      two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study
      duration will be 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of herbal treatment (SA100) as assessed by clinical and laboratory adverse events.</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mayo Score</measure>
    <time_frame>Screening/Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire (SIBDQ)</measure>
    <time_frame>Screening/Baseline, Week 2, 4, 6, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker levels</measure>
    <time_frame>Screening/Baseline, Week 2, 4, 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Herbal treatment (SA100) 500 mg/day (250 mg twice per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herbal treatment (SA100)</intervention_name>
    <description>This treatment has been used extensively in traditional medicine practices for hundreds of years.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Age ≥ 18 years and ≤ 75 years.

          2. Mild-to-moderate ulcerative colitis (biopsy-proven).

          3. Mayo Scoring System Assessment of Ulcerative Colitis Activity score of 3 to 10 at
             screening.

          4. Patients with active disease who are refractory to, intolerant to, or unwilling to
             take 5-aminosalicylic acid (5-ASA).

          5. Physician's Global Assessment (PGA) Mayo subscore of at least 1 at screening.

          6. Mayo rectal bleeding subscore of at least 1 at screening.

          7. Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy
             with Mayo mucosal appearance subscore of at least 1 at screening.

          8. Female patients of child-bearing potential must have a negative serum pregnancy test
             at the screening visit and agree to use two medically reliable methods of
             contraception (such as barrier with either spermicide or hormonal contraception)
             during the study period.

          9. Male patients must be willing to use acceptable contraceptive methods and assure that
             their female partners of child-bearing potential use acceptable contraceptive methods
             during the study period.

         10. Ability to adhere to the study visit schedule and other protocol requirements.

         11. Adequate cardiac, renal, and hepatic function as determined by the principal
             investigators.

         12. Written informed consent will be obtained before any study procedure is performed.

        Exclusion Criteria:

          1. Are nursing or pregnant.

          2. Patients who are in critical condition

          3. Crohn's disease or indeterminate colitis.

          4. Known sensitivity to any ingredients in the study drug.

          5. A change in therapy within 2 weeks before the baseline visit.

          6. Use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.).

          7. Diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or any
             other unstable medical condition.

          8. Any clinically meaningful laboratory abnormality that in the judgment of the
             investigator should preclude participation in the study.

          9. Impaired renal function (serum creatinine levels &gt;2.0 mg/dL) at screening.

         10. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values &gt;1.5
             times upper limit of normal at screening.

         11. Diagnosis of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter,
             enteropathogenic E. coli in stool.

         12. Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen
             (HBsAg) at screening.

         13. Active malignancy (except basal cell carcinoma).

         14. Active alcohol or drug abuse.

         15. Tobacco smoking within 2 weeks before study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berkeley Limketkai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali Al-Rajhi, Ph.D.</last_name>
    <phone>650 721 4284</phone>
    <email>alrajhi@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>May 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Berkeley Limketkai</investigator_full_name>
    <investigator_title>Dr. Berkeley Limketkai</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

